A Research Study and Report on the Role of Clinical Pharmacy Services on the Management of Chronic Respiratory Disorder Asthma to an ESI Hospital

Authors

  • Rohit Chandrakant Kamble Pharm. D 5th year Student, Department of Pharmacy Practice, Gautham College of Pharmacy, RT Nagar, Bangalore, Karnataka, India
  • Mekkanti Manasa Rekha Pharm.D, RCPh, (Ph.D), FSASS, Assistant Professor, Scientist ,Department of Pharmacy Practice, Gautham College of Pharmacy, RT Nagar, Bangalore, Karnataka, India and Research scholar in MS. Ramaiah University of Applied sciences, Bangalore, Karnataka, India
  • Rinku Mathappan M.Pharm, Ph.D., Principal and Professor, Department of Pharmacognosy, Gautham College of Pharmacy, RT Nagar, Bangalore, Karnataka, India.

Keywords:

chronic respiratory disorder (CRDs), asthma, COPD, pulmonary hypertension, prevalence, socioeconomic.

Abstract

Chronic respiratory disorder (CRDs) are disease of the airways and other structure of the lung. A number of the foremost common are asthma, chronic obstructive pulmonary disease (COPD), occupational lung diseases and pulmonary hypertension. Additionally, to tobacco smoke, other risk factors including air pollution, occupational chemicals and dusts, and frequent lower respiratory infections during childhood. CRDs aren’t curable, however kinds of treatment that help dilate major air passages and improve shortness of breath can help control symptoms and increase the standard of life for people with the disease. Epidemiologically the burden of asthma in India is alarming with the median prevalence of 7%. As the symptoms of asthma ascend the severity ladder, the prediction on the rationale behind asthma is important from the treatment point of view. The goal of asthma treatment is to achieve good control of symptom, to cut back exacerbation and to boost quality of life, the burden of asthma is immense, with over 300 million individuals currently laid low with asthma worldwide, about a tenth of these living in India. Asthma causes limitations in daily activities, loss of school and work days, lung function impairment, and adverse socioeconomic burden. There are about 4 lakh deaths due to asthma annually and also the majority of deaths occur in low- and middleincome countries because of incorrect diagnosis, poor access to health care.

References

Boulet LP. Pocket Guide for Asthma Management and Prevention.; 2019. https://ginasthma.org/wp-content/uploads/2019/04/GINA-2019-main-Pocket-Guide-wms.pdf.

Salvi SS, Apte KK, Dhar R, et al. Asthma insights and management in India: Lessons learnt from the Asia Pacific - Asthma insights and management (AP-AIM) study. J Assoc Physicians India 2015; 63:36-43.

Koul PA, Patel D. Indian guidelines for asthma: Adherence is the key Indian guidelines for asthma: Adherence is the key Indian guidelines for asthma: Adherence is the key. Lung India 2019; 32(Supple 1):10-12. doi:10.4103/0970-2113.154511

Salvi SS. The burden of chronic respiratory diseases and their heterogeneity across the states of India:The Global Burden of Disease Study 1990 – 2016. Lancet 2018; 6: e478–89. doi:10.1016/S2214-109X (18)30409-1

NHLBI, national asthma education and prevention program, expert panel report 2. Guidelines for the diagnosis and management of asthma. NIH publication No. 97-4051. Bethesda, MD, US department of health and human services, 1997.

Campbell SC. Clinical aspects of inhaled anticholinergic therapy. Respiratory care 2000; 45:864-867.

Plotnick LH, Ducharme FM. Should inhaled anticholinergic be added to β2-agonist for treating acute childhood and adolescent asthma? A systematic review. Br Med J 1998; 317:971-977.

National institutes of health, national heart, lung, and blood institute. Global initiative for asthma (GINA). Global strategy for asthma management and prevention revised (2002). NHLBI/WHO workshop report. NIH publication No. 02-3659. Bethesda, MD, US department of health and human service, 2002.

Sorkness CA. cromolyn, nedocromil, leukotriene modifiers, and alternative anti-inflammatory agents in the treatment of paediatric asthma. In: murphy SA, Kelly HW, eds. Paediatric asthma. New York. Marcel Dekker, 1999:433-462.

Sorkness CA. leukotriene receptor antagonists in the treatment of asthma. Pharmacotherapy 2001; 21:34S-37S.

Price D. Tolerability of montelukast. Drugs 2000;59(supple 1):35-42.

Barsukiewics, Camille k; Raffle, Marshall w; RaffleNorma K (2010). The U.S health system: originsand function, sixth edition. Clifton Park, NY: can gage learning P .80. ISBN 978-1-4180-5298-0

American college of clinical pharmacy (June 2008). The definition of clinical pharmacy. Pharmacotherapy.28(6):816-7.

Greer N, Bolduc j, Geurkick E, Rector T, Olson K, Koeller E, MacDonald R, Wilt TJ (April 16). Pharmacist-; ed chronic disease management: A systematic review of effectiveness and harms compared with usual care. Annals of internal medicine.165(1):30-40.

Hoti k, Hughes J, Sunderland B (2011-04-30). An expanded prescribing role for pharmacists-An Australian perspective. The Australian medical journal.4(4):236-42

Collaborative drug therapy management (CDTM). Pharmacist’s letter / prescribers’ letter.25:250801.2009.

Downloads

Published

2021-09-18

Issue

Vol. 12 No. 2 (2021)

Section

Research Article

License

Declaration and Copyright Transfer Form

(to be completed by authors)

I/ We, the undersigned author(s) of the submitted manuscript, hereby declare, that the above manuscript which is submitted for publication in the STM Journals(s), is not published already in part or whole (except in the form of abstract) in any journal or magazine for private or public circulation, and, is not under consideration of publication elsewhere.

  • I/We will not withdraw the manuscript after 1 week of submission as I have read the Author Guidelines and will adhere to the guidelines.
  • I/We Author(s ) have niether given nor will give this manuscript elsewhere for publishing after submitting in STM Journal(s).
  • I/ We have read the original version of the manuscript and am/ are responsible for the thought contents embodied in it. The work dealt in the manuscript is my/ our own, and my/ our individual contribution to this work is significant enough to qualify for authorship.
  •  I/We also agree to the authorship of the article in the following order:

Author’s name                                    

 

1. ________________

2. ________________

3. ________________

4. ________________

 

We  Author(s) tick this box and would request you to consider it as our signature as we agree to the terms of this Copyright Notice, which will apply to this submission if and when it is published by this journal.